Although TDP-43 appears to be raised in either plasma or CSF of clinically defined FTD or FTD-MND populations, there is significant overlap with control or AD subjects and it remains unclear if such an approach will prove clinically useful (Foulds et al., 2008; Steinacker et al., 2008). Here, TARDBP is linked to mild neurocognitive disorder.